Elekta and Philips deepen strategic partnership in precise and individualized oncology care
Elekta and Royal Philips have expanded their strategic partnership to enhance cancer care through precision oncology solutions. This collaboration focuses on improving magnetic resonance (MR)-guided adaptive radiation therapy, enabling quicker tumor visualization, optimal treatment strategies, and effective therapy delivery. The partnership aims to bolster personalized treatments for patients while lowering healthcare costs. Elekta's President and CEO, Gustaf Salford, emphasizes the potential for better cancer outcomes through integrated systems. The agreement showcases a commitment to advancing oncology technologies.
- Extended partnership enhances precision oncology solutions.
- Improved patient outcomes through quicker tumor visualization and optimal treatment strategies.
- Lowered costs of care for healthcare providers.
- Commitment to personalized treatments in cancer care.
- None.
STOCKHOLM and AMSTERDAM, June 7, 2021 /PRNewswire/ -- Elekta (EKTA-B.ST) and Royal Philips (NYSE: PHG, AEX: PHIA) today signed agreements to deepen their existing strategic partnership to advance comprehensive and personalized cancer care through precision oncology solutions.
The extended collaboration builds on the two companies' successful cooperation in the fast-emerging field of magnetic resonance (MR)-guided adaptive radiation therapy. Through deeper cross-portfolio collaboration, Elekta and Philips will utilize their complementary capabilities to further improve patient care.
Benefiting patients throughout the care pathway
Oncology care is transforming, driven by an increasingly precise diagnosis of each tumor, and a continuously expanding range of therapy options. To fully capitalize on these opportunities, healthcare providers require integrated solutions throughout the entire cancer care pathway, from diagnosis to treatment and follow-up.
This integrated approach has the potential to provide:
- Quicker, more accurate visualization of the tumor
- Easier decision of optimal treatment strategy
- Earlier assessment of therapy response
- More effective and efficient therapy delivery
The strengthened strategic partnership intends to further deliver a superior experience in diagnosis and adaptive, personalized treatments for clinicians, shorter treatment times and more precise therapy for patients, and lowered costs of care for healthcare providers.
"I expect this extended partnership to unlock opportunities that will provide better outcomes for people with cancer," said Gustaf Salford, Elekta's President and CEO. "Together, we'll combine advanced informatics and image-guided RT solutions to deliver greater precision in oncology. This means easier selection by clinicans of the optimal treatment strategy and more efficient and effective therapy delivery."
"To capitalize on the opportunities presented by increasingly precise diagnosis and the fast-expanding range of therapies available for cancer patients, it's essential to provide integrated systems and solutions that provide the right insights at the right time throughout each patient's care journey," said Kees Wesdorp, Chief Business Leader of Precision Diagnosis at Philips. "By deepening our already-successful collaboration with Elekta, we will accelerate towards our goal of providing clear care pathways and predictable outcomes for every cancer patient. Today's announcement is an important next step in the implementation of our strategy in precision diagnosis."
In this preferred, although non-exclusive, partnership, Elekta and Philips will leverage their capabilities to pursue integrated vendor-agnostic solutions, enhancing interoperability between the two parties' systems and software in order to drive precision in oncology.
For further information, please contact:
Mattias Thorsson, Vice President, Head of Corporate Communications
Tel: +46 70 865 8012, e-mail: Mattias.Thorsson@elekta.com
Time zone: CET: Central European Time
Cecilia Ketels, Head of Investor Relations
Tel: +46 76 611 76 25, e-mail: cecilia.ketels@elekta.com
Time zone: CET: Central European Time
Mark Groves, Philips Global Press Office
Tel: +31 631 639 916, e-mail: mark.groves@philips.com
Time zone: CET: Central European Time
This is information that Elekta AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication at 08:30 CEST on June 7, 2021. (REGMAR)
About Elekta
For almost five decades, Elekta has been a leader in precision radiation medicine. Our more than 4,000 employees worldwide are committed to ensuring everyone in the world with cancer has access to – and benefits from – more precise, personalized radiotherapy treatments. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm Exchange. Visit elekta.com or follow @Elekta on Twitter.
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2020 sales of EUR 17.3 billion and employs approximately 77,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Elekta-Philips_press release_final | |
Elekta Unity |
View original content:http://www.prnewswire.com/news-releases/elekta-and-philips-deepen-strategic-partnership-in-precise-and-individualized-oncology-care-301306595.html
SOURCE Elekta
FAQ
What is the significance of Elekta and Philips's partnership announced on June 7, 2021?
What type of therapy is being improved through the Elekta and Philips collaboration?
How does the Elekta and Philips partnership benefit cancer patients?
What is the stock symbol for Elekta?
